Autoimmune Brain Panel™

Live Q&A

Navigating Anti-Neuronal Antibody Testing for Neuropsychiatric Disorders

Autoimmune Brain Panel™ in clinical practice

For a subset of patients, chronic anxiety, OCD, mood changes, and behavioral symptoms may reflect an underlying immune-mediated process affecting the nervous system — often times following an infection — rather than a primary psychiatric condition alone. When symptoms persist despite appropriate psychotropic treatment, clinicians may consider whether an autoimmune or neuroinflammatory contributor could be involved.

HAVE QUESTIONS ABOUT TESTING?

Join Us for a Live Q&A

PRESENTER: Craig Shimasaki, PhD, MBA, President & CEO, Moleculera Biosciences
DATE: Friday, November 6th
TIME: 12pm CT

ABOUT WEBINAR

This 45-minute discussion will provide a brief overview of testing with the Autoimmune Brain Panel™ (formerly the Cunningham Panel™) and its potential role in evaluating patients with neuropsychiatric symptoms that may have an autoimmune component.

There were will ample time for Q&A, including discussion of your patient cases and questions about testing.

We'll review:
  • The underlying science of immune-mediated neuropsychiatric conditions.
  • Key clinical indicators: Identifying candidates for Autoimmune Brain Panel™ testing.
  • How to evaluate and apply test results.
  • Review real-world patient cases ─ including Panel results and treatment outcomes.
  • Live Q&A